The White House is announcing a new round of voluntary drug pricing deals with nearly a dozen mid-sized biotech firms today. Mega-caps like Pfizer and Eli Lilly absorbed the initial wave of these "most-favored-nation" Medicaid discounts, mid-caps operate on thinner margins and have less diversified pipelines. Should we view these "voluntary" concessions as a structural threat to mid-tier biotech cash flows, or will tariff relief and regulatory shortcuts offset the pricing pre
CryptoAlerta — análise de criptomoedas e mercado em tempo real